hC Bioscience

hC Bioscience is committed to improving patients' lives by developing first-class tRNA-based therapies targeting protein dysfunction. hC Bioscience's innovative precision protein editing approach has the potential to treat genetically defined diseases, which account for 10-15% of all human diseases.